ARA-290 vs Orexin A
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Also: Hypocretin-1, Hcrt-1
Orexin A (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. People with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. Orexin A itself is not an approved drug, but a few small German studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. Interesting science, very early stage.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | ARA-290 | Orexin A |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. | Orexin A activates both orexin receptors (OX1R and OX2R) with high affinity. Those receptors sit on brainstem and hypothalamic arousal centers (the histamine, noradrenaline, dopamine and acetylcholine systems), so orexin acts like a stabilizer that keeps the brain locked in the wake state and stops it slipping into REM sleep at the wrong time. Losing it causes narcolepsy: orexin knockout mice and dogs with a broken OX2R gene both develop narcolepsy, and giving orexin A into the brain of narcoleptic mice suppressed cataplexy. Orexin also drives appetite and raises sympathetic nerve activity. A mouse study found orexin A crosses the blood-brain barrier fairly well, and the nasal route is used in humans to deliver more of it to the brain. |
| Common Dosing | 4 mg daily Once daily | 435 nmol (about 1.5 mg) intranasal Single dose in studies |
| Administration | Subcutaneous injection | Intranasal spray |
| Typical Duration | 28-day courses in trials | Single doses only in published human studies |
| Best Time to Take | Consistent daily timing | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. | The human data comes from a handful of small, placebo-controlled crossover studies, mostly from one group in Kiel, Germany. In 2008, intranasal orexin A improved smell detection thresholds in 7 narcolepsy patients. In 2011, a single 435 nmol nasal dose before bed in 8 patients did not change nighttime wakefulness but reduced REM sleep and wake-to-REM transitions. In 2014, the same dose given in the morning to 14 patients reduced wake-REM transitions and improved divided attention (fewer errors). In 2022, 500 nmol in 10 healthy men acutely raised sympathetic nerve activity to blood vessels, without changing blood pressure or heart rate. In sleep-deprived monkeys, nasal orexin A reversed some of the drop in memory performance (Deadwyler, 2007). That is the whole human record: single doses, tiny groups, short-term outcomes. The real clinical action has moved to small-molecule drugs that mimic orexin at OX2R. Takeda's oveporexton (brand name Orzeyful) was FDA-approved on August 5, 2026 for narcolepsy type 1, which validates the target but is not the same thing as using the peptide. |
Frequently Asked Questions: ARA-290 vs Orexin A
What is the difference between ARA-290 and Orexin A?
ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. Orexin A is a cognitive peptide that orexin a (also called hypocretin-1) is a 33-amino-acid brain peptide made by a small cluster of neurons in the hypothalamus, and it is one of the main signals that keeps you awake. people with narcolepsy type 1 have lost most of these neurons, and orexin is undetectable in their spinal fluid. orexin a itself is not an approved drug, but a few small german studies have sprayed it into the nose of narcolepsy patients and healthy men with measurable effects. interesting science, very early stage. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or Orexin A?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while Orexin A is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and Orexin A be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and Orexin A together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.